J. Clubb

1203P Clinical correlations and long-term survival in PROTA: Platinum-resistant or refractory ovarian cancer treated with an oncolytic adenovirus encoding TNF and IL2 in combination with pembrolizumab

N. Ojala, J. Clubb, Matthew S. Block, Johanna Mäenpää et autres

fi, gb, us (code pays fourni par la source)

Abstract 2035: Clinical-immunological correlates in platinum resistant or refractory ovarian cancer patients treated with chimeric oncolytic adenovirus encoding TNFa and IL-2 (TILT-123) in combination with pembrolizumab

J. Clubb, Matthew S. Block, Johanna Mäenpää, Victor Arias et autres

Abstract Background: Ad5/3-E2F-D24-hTNFa-IRES-hIL-2 (TILT-123) is an oncolytic adenovirus armed with TNFa and IL-2. The cytokine pairing demonstrated superior tumor immunomodulation in preclinical studies. Subsequent studies supported evaluation of TILT-123 in PROTA, a phase 1 study of TILT-123 in combination with pembrolizumab in …

us, fi (code pays fourni par la source)

6MO Single-cell analysis of peripheral blood mononuclear cells reveals therapy outcomes are associated with pre-existing immunity in patients treated with oncolytic adenovirus armed with TNFα and IL2

Tatiana V. Kudling, Dmitrii Bychkov, J. Clubb, Santeri A. Pakola et autres

Engineered oncolytic adenovirus Ad5/3-E2F-d24-hTNFa-IRES-hIL2 (TILT-123) has emerged as a promising candidate for clinical translation due to its ability to induce tumor regression and activate host immunity. The phase 1 clinical trial TUNIMO (NCT04695327) assessed the safety of TILT-123 in patients with advanced …

fi, gb (code pays fourni par la source)

127P Combining chemotherapy and checkpoint inhibitors with an engineered oncolytic adenovirus encoding a human vIL-2 cytokine to treat pancreatic ductal adenocarcinoma

N. Ojala, Santeri A. Pakola, T. Kudling, J. Clubb et autres

fi, gb (code pays fourni par la source)

1025P Fully intravenous delivery regimen of oncolytic adenovirus coding for TNFa and IL-2 (TILT-123) in patients with advanced solid cancers

Santeri A. Pakola, K. Jalkanen, Tuomo Alanko, J. Clubb et autres

fi, gb (code pays fourni par la source)

Abstract CT139: Immunological activity of oncolytic adenovirus encoding TNFα and IL-2 (TILT-123) in combination with pembrolizumab in platinum resistant or refractory ovarian cancer patients

J. Clubb, Matthew S. Block, Johanna Mäenpää, Santeri A. Pakola et autres

Abstract Background TILT-123 (Ad5/3-E2F-D24-hTNFα-IRES-hIL-2) is a serotype chimeric dual safety device oncolytic adenovirus armed with tumor necrosis factor alpha and interleukin-2. It was designed to improve efficacy of T-cell therapies such as immune checkpoint blockade or adoptive cell transfer. We present biological …

us, fi (code pays fourni par la source)

48O Safety and efficacy of combined treatment with tumor infiltrating lymphocytes (TILs) and oncolytic adenovirus TILT-123 for patients with metastatic melanoma: Results from a phase I trial

Tine Monberg, Santeri A. Pakola, Brigitte Dréno, Víctor Cervera-Carrascón et autres

Tumor Infiltrating Lymphocyte (TIL) therapy has recently proved effective in patients with metastatic melanoma. Oncolytic adenovirus TILT-123 (igrelimogene litadenorepvec) is armed with tumor necrosis factor-alpha and interleukin-2 which were selected specifically for their ability to enhance TIL cytotoxicity without the need for …

dk, fi, fr (code pays fourni par la source)

52P MUC1 targeted immunotherapy with an oncolytic adenovirus coding for a bispecific T cell engager

Saru Basnet, J.M. Santos, D.C.A. Quixabeira, J. Clubb et autres

Bispecific T cell engager (BsTe) is a fusion recombinant protein comprised of two single–chain variable fragments with dual specificity for a tumor–associated antigen (TAA) and T cell receptor (usually CD3ε). Immunotherapy with BsTe has shown efficacy in patients with hematologic malignancies and …

fi (code pays fourni par la source)

50P Enhancing TIL and NK cells adoptive therapies with an engineered oncolytic adenovirus encoding a human vIL-2 cytokine for the treatment of human ovarian cancer

Dafne C.A. Quixabeira, Santeri A Pakola, E. Jirovec, S. Basnet et autres

Tumor-infiltrating lymphocytes (TILs) and natural killer (NK) adoptive cell therapies have shown promising results in advanced-stage melanoma and haematological malignancies, respectively. However, their limited persistence in vivo in absence of an exogenous source of IL-2, and migration to neoplastic sites have impaired …

fi (code pays fourni par la source)